OWOlga Will

Olga Will

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga Will has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Carolin Kubelt

    Department of Neurosurgery, University Medical Center Schleswig-Holstein UKSH, Campus Kiel, 24105 Kiel, Germany

    1 shared publication
  • Dana Hellmold

    Department of Neurosurgery, University Medical Center Schleswig-Holstein UKSH, Campus Kiel, 24105 Kiel, Germany

    1 shared publication
  • Eva Peschke

    Section Biomedical Imaging, Molecular Imaging North Competence Center (MOIN CC), Department of Radiology and Neuroradiology, University Medical Center Kiel, Kiel University, Am Botanischen Garten 14, 24118 Kiel, Germany

    1 shared publication
  • Fabian Schütt

    Functional Nanomaterials, Department of Materials Science, Kiel University, 24143 Kiel, Germany

    1 shared publication
  • Jan-Bernd Hövener

    Section Biomedical Imaging (SBMI), Molecular Imaging North Competence Center (MOINCC), Department of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany

    1 shared publication
  • Janka Held-Feindt

    Department of Neurosurgery University Medical Center Schleswig‐Holstein (UKSH) Kiel Germany

    1 shared publication

Latest Publications

  • Open Access

    Establishment of a Rodent Glioblastoma Partial Resection Model for Chemotherapy by Local Drug Carriers—Sharing Experience

    by Carolin Kubelt, Dana Hellmold, Eva Peschke, Margarethe Hauck, Olga Will, Fabian Schütt, Ralph Lucius, Rainer Adelung, Regina Scherließ, Jan-Bernd Hövener, et al.

    Local drug delivery systems (LDDS) represent a promising therapy strategy concerning the most common and malignant primary brain tumor glioblastoma (GBM). Nevertheless, to date, only a few systems have been clinically applied, and their success is very limited. Still, numerous new LDDS approaches are currently being developed. Here, (partial resection) GBM animal models play a key role, as such models are needed to evaluate the therapy prior to any human application. However, such models are complex to establish, and only a few reports detail the process. Here, we report our results of establishing a partial resection glioma model in rats suitable for evaluating LDDS. C6-bearing Wistar rats and U87MG-spheroids- and patient-derived glioma stem-like cells-bearing athymic rats underwent tumor resection followed by the implantation of an exemplary LDDS. Inoculation, tumor growth, residual tumor tissue, and GBM recurrence were reliably imaged using high-resolution Magnetic Resonance Imaging. The release from an exemplary LDDS was verified in vitro and in vivo using Fluorescence Molecular Tomography. The presented GBM partial resection model appears to be well suited to determine the efficiency of LDDS. By sharing our expertise, we intend to provide a powerful tool for the future testing of these very promising systems, paving their way into clinical application.